Sarepta Therapeutics
SRPT
151 hedge funds and large institutions have $1.1B invested in Sarepta Therapeutics in 2015 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 67 increasing their positions, 38 reducing their positions, and 19 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
85% more call options, than puts
Call options by funds: $184M | Put options by funds: $99.4M
76% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 38
23% more capital invested
Capital invested by funds: $891M → $1.1B (+$209M)
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
1% more funds holding
Funds holding: 149 → 151 (+2)
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$47.5M |
| 2 |
Jennison Associates
New York
|
+$22.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$21.1M |
| 4 |
Millennium Management
New York
|
+$13.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.47M |
Top Sellers
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$31.4M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$19M |
| 3 |
PA
Perceptive Advisors
New York
|
-$17.6M |
| 4 |
D.E. Shaw & Co
New York
|
-$11.9M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$11.7M |
SRPT Hedge Fund Activity: Q4 2015 in Review
151 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2015, worth a combined $1.1B — up 23% from $891M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SRPT positions and 19 closed out — a net gain of 3 holders — while 67 added to existing stakes and 38 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $47.5M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $31.4M.
- 151 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2015, up from 149 in Q3 2015.
- Funds reported $1.1B of Sarepta Therapeutics stock for Q4 2015, up 23% quarter-over-quarter.
- 22 funds opened new Sarepta Therapeutics positions in Q4 2015 and 19 closed out, a net change of +3 holders.
- The largest Sarepta Therapeutics buyer in Q4 2015 was Point72 Asset Management, an estimated $47.5M added.
- The largest Sarepta Therapeutics seller in Q4 2015 was Columbia Wanger Asset Management, an estimated $31.4M sold.
Based on aggregated 13F filings for Q4 2015.